The expression of CTLA-4 was enriched in both CD8 and non-CD8 T cells in the tumour relative to the blood with varying proportions of CTLA-4+ T cells which might predict a widely varied response to checkpoint blockade therapies. The gene discussed is CTLA4; the disease is neoplasm.